Sun Pharmaceutical Industries Limited SUNPHARMA.NS

Name: SUNPHARMA.NS quality scores
Creator: Stocktoria
License: https://stocktoria.com/terms/

IN · National Stock Exchange of India · XNSE · stock · Healthcare · website

Sun Pharmaceutical Industries Limited (SUNPHARMA.NS) earns a Piotroski F-score of 5/9 (mixed financial health). It pays a dividend yielding 0.87% (safety: safe). FY2026 revenue was $582.2B at a 19.7% net margin.

5/9

Piotroski F — financial health

—

Altman Z″ — distress risk

34.3%

Dividend payout · safe

$1,862.50 as of 2026-06-01 · +11.1% 1y

$1,594.30$1,862.5052-wk

Price from month-end closes (Yahoo) — for reference, not real-time.

Market cap$4.52T

P / E39.4×

Dividend yield0.87%

Net margin19.7%

Return on equity13.7%

Revenue trend · last 4y · up

How it ranks in Healthcare · percentile among 36 companies

Piotroski Fstronger than 11%

Net marginstronger than 74%

Return on equitystronger than 54%

Revenue growthstronger than 78%

Percentile vs other Healthcare companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.

Piotroski F breakdown · 5/9 tests passed

Positive return on assets
Positive operating cash flow
Rising ROA
Cash flow exceeds net income
Lower long-term debt
Rising current ratio
No share dilution
Rising gross margin
Rising asset turnover

FAQ

Is SUNPHARMA.NS financially healthy?

Sun Pharmaceutical Industries Limited's Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak).

Does SUNPHARMA.NS pay a dividend, and is it safe?

Yes. Sun Pharmaceutical Industries Limited pays a dividend yielding about 0.87% with a 34.3% payout ratio, rated “safe” for safety.

How profitable is SUNPHARMA.NS?

In FY2026, Sun Pharmaceutical Industries Limited had a net margin of 19.7% and a return on equity of 13.7%.

Source: company filings via Yahoo Finance · IN · as of 2026-03-31. Figures in INR; non-US fundamentals are aggregated by Yahoo (shorter history); facts plus Stocktoria's own computed scores — not investment advice.